Arrowhead Pharmaceuticals Stock Price To Sales

ARWR Stock

USD 26.03 0.12 0.46%

Arrowhead Pharmaceuticals fundamentals help investors to digest information that contributes to Arrowhead Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Arrowhead Stock. The fundamental analysis module provides a way to measure Arrowhead Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arrowhead Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	653.40	686.07

As of 12/01/2024, Price To Sales Ratio is likely to grow to 686.07.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arrowhead Pharmaceuticals Company Price To Sales Analysis

Arrowhead Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Arrowhead Pharmaceuticals Price To Sales

165.61 X

Most of Arrowhead Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arrowhead Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arrowhead Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Arrowhead Pharmaceuticals is extremely important. It helps to project a fair market value of Arrowhead Stock properly, considering its historical fundamentals such as Price To Sales. Since Arrowhead Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arrowhead Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arrowhead Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Property Plant Equipment	Good Will	Short Term Investments	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.44	0.15	-0.95	0.52	0.16	0.94	0.99	0.66	0.2	0.25	0.9	0.89	0.17	0.96	-0.05	0.68	0.39	0.97	0.23	-0.18	0.95	0.1	0.79	0.92	0.19
Total Stockholder Equity	0.44		-0.59	-0.25	0.4	0.48	0.12	0.43	0.36	-0.1	0.52	0.63	0.13	0.3	0.23	0.22	0.79	0.34	0.5	0.26	-0.32	0.43	0.16	0.72	0.27	-0.1
Net Debt	0.15	-0.59		-0.32	0.12	-0.38	0.38	0.11	-0.16	0.12	-0.62	-0.13	0.47	-0.2	0.37	-0.3	-0.32	-0.02	0.12	-0.15	0.28	0.26	-0.16	-0.12	0.19	0.12
Retained Earnings	-0.95	-0.25	-0.32		-0.53	0.03	-0.96	-0.95	-0.59	-0.14	-0.04	-0.77	-0.94	-0.28	-0.97	-0.05	-0.49	-0.45	-0.93	-0.31	0.21	-0.92	-0.14	-0.69	-0.89	-0.14
Accounts Payable	0.52	0.4	0.12	-0.53		-0.03	0.43	0.49	0.6	-0.15	-0.04	0.5	0.65	0.29	0.44	0.12	0.28	0.35	0.55	0.38	-0.18	0.65	0.13	0.39	0.2	-0.15
Net Receivables	0.16	0.48	-0.38	0.03	-0.03		0.01	0.11	0.07	0.03	0.74	0.26	-0.15	0.03	0.0	0.01	0.4	0.21	0.15	0.04	-0.14	0.21	-0.03	0.3	0.06	0.03
Total Liab	0.94	0.12	0.38	-0.96	0.43	0.01		0.94	0.61	0.27	0.1	0.77	0.93	0.09	0.98	-0.14	0.48	0.32	0.89	0.17	-0.08	0.89	0.05	0.61	0.91	0.27
Total Current Assets	0.99	0.43	0.11	-0.95	0.49	0.11	0.94		0.67	0.15	0.22	0.9	0.89	0.17	0.96	-0.04	0.66	0.37	0.95	0.22	-0.18	0.93	0.11	0.79	0.93	0.15
Short Term Debt	0.66	0.36	-0.16	-0.59	0.6	0.07	0.61	0.67		0.16	0.46	0.81	0.62	0.14	0.55	-0.03	0.49	0.33	0.65	0.17	-0.12	0.59	0.03	0.49	0.5	0.16
Common Stock	0.2	-0.1	0.12	-0.14	-0.15	0.03	0.27	0.15	0.16		0.42	0.26	0.03	0.07	0.16	-0.01	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.17	1.0
Current Deferred Revenue	0.25	0.52	-0.62	-0.04	-0.04	0.74	0.1	0.22	0.46	0.42		0.51	-0.13	0.19	0.03	0.16	0.61	0.28	0.3	0.18	-0.18	0.12	0.05	0.27	0.16	0.41
Long Term Debt	0.9	0.63	-0.13	-0.77	0.5	0.26	0.77	0.9	0.81	0.26	0.51		0.7	0.19	0.79	0.01	0.82	0.45	0.9	0.24	-0.18	0.81	0.07	0.81	0.8	0.26
Property Plant Equipment	0.89	0.13	0.47	-0.94	0.65	-0.15	0.93	0.89	0.62	0.03	-0.13	0.7		0.08	0.94	-0.15	0.34	0.3	0.83	0.16	-0.06	0.91	0.04	0.6	0.8	0.03
Good Will	0.17	0.3	-0.2	-0.28	0.29	0.03	0.09	0.17	0.14	0.07	0.19	0.19	0.08		0.1	0.94	0.17	0.52	0.31	0.64	-0.45	0.15	0.72	0.2	0.09	0.07
Short Term Investments	0.96	0.23	0.37	-0.97	0.44	0.0	0.98	0.96	0.55	0.16	0.03	0.79	0.94	0.1		-0.12	0.52	0.33	0.91	0.16	-0.09	0.93	0.06	0.72	0.94	0.16
Intangible Assets	-0.05	0.22	-0.3	-0.05	0.12	0.01	-0.14	-0.04	-0.03	-0.01	0.16	0.01	-0.15	0.94	-0.12		0.01	0.39	0.1	0.57	-0.42	-0.07	0.72	-0.01	-0.08	-0.01
Net Tangible Assets	0.68	0.79	-0.32	-0.49	0.28	0.4	0.48	0.66	0.49	0.4	0.61	0.82	0.34	0.17	0.52	0.01		0.32	0.75	0.2	-0.32	0.56	0.05	0.72	0.56	0.4
Long Term Debt Total	0.39	0.34	-0.02	-0.45	0.35	0.21	0.32	0.37	0.33	0.13	0.28	0.45	0.3	0.52	0.33	0.39	0.32		0.47	0.76	-0.42	0.37	-0.13	0.42	0.33	0.13
Capital Surpluse	0.97	0.5	0.12	-0.93	0.55	0.15	0.89	0.95	0.65	0.3	0.3	0.9	0.83	0.31	0.91	0.1	0.75	0.47		0.35	-0.29	0.9	0.15	0.74	0.85	0.3
Deferred Long Term Liab	0.23	0.26	-0.15	-0.31	0.38	0.04	0.17	0.22	0.17	0.08	0.18	0.24	0.16	0.64	0.16	0.57	0.2	0.76	0.35		-0.28	0.21	0.03	0.23	0.16	0.08
Accumulated Depreciation	-0.18	-0.32	0.28	0.21	-0.18	-0.14	-0.08	-0.18	-0.12	-0.09	-0.18	-0.18	-0.06	-0.45	-0.09	-0.42	-0.32	-0.42	-0.29	-0.28		-0.12	-0.26	-0.11	-0.07	-0.09
Long Term Investments	0.95	0.43	0.26	-0.92	0.65	0.21	0.89	0.93	0.59	-0.03	0.12	0.81	0.91	0.15	0.93	-0.07	0.56	0.37	0.9	0.21	-0.12		0.09	0.79	0.82	-0.03
Short Long Term Debt	0.1	0.16	-0.16	-0.14	0.13	-0.03	0.05	0.11	0.03	0.02	0.05	0.07	0.04	0.72	0.06	0.72	0.05	-0.13	0.15	0.03	-0.26	0.09		0.04	0.04	0.02
Net Invested Capital	0.79	0.72	-0.12	-0.69	0.39	0.3	0.61	0.79	0.49	-0.16	0.27	0.81	0.6	0.2	0.72	-0.01	0.72	0.42	0.74	0.23	-0.11	0.79	0.04		0.76	-0.16
Net Working Capital	0.92	0.27	0.19	-0.89	0.2	0.06	0.91	0.93	0.5	0.17	0.16	0.8	0.8	0.09	0.94	-0.08	0.56	0.33	0.85	0.16	-0.07	0.82	0.04	0.76		0.17
Capital Stock	0.19	-0.1	0.12	-0.14	-0.15	0.03	0.27	0.15	0.16	1.0	0.41	0.26	0.03	0.07	0.16	-0.01	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.17

Click cells to compare fundamentals

Arrowhead Price To Sales Historical Pattern

Today, most investors in Arrowhead Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arrowhead Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arrowhead Pharmaceuticals price to sales as a starting point in their analysis.

Arrowhead Pharmaceuticals Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Arrowhead Pharmaceuticals

Price To Sales Ratio Over Time

Arrowhead Price To Sales Ratio

Price To Sales Ratio

686.07

At this time, Arrowhead Pharmaceuticals' Price To Sales Ratio is relatively stable compared to the past year.

Based on the latest financial disclosure, Arrowhead Pharmaceuticals has a Price To Sales of 165 times. This is much higher than that of the Biotechnology sector and 68.29% higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.

Arrowhead Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.

Arrowhead Pharmaceuticals is currently under evaluation in price to sales category among its peers.

Arrowhead Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Arrowhead Pharmaceuticals from analyzing Arrowhead Pharmaceuticals' financial statements. These drivers represent accounts that assess Arrowhead Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arrowhead Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.6B	2.6B	4.3B	3.5B	3.1B	3.3B
Enterprise Value	1.6B	2.4B	4.2B	3.5B	3.1B	3.3B

Arrowhead Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arrowhead Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arrowhead Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Arrowhead Fundamentals

	Return On Equity	-1.52
	Return On Asset	-0.41
	Operating Margin	(27.85) %
	Current Valuation	3.07 B
	Shares Outstanding	124.43 M
	Shares Owned By Insiders	4.46 %
	Shares Owned By Institutions	79.70 %
	Number Of Shares Shorted	9.45 M
	Price To Earning	482.39 X
	Price To Book	17.47 X
	Price To Sales	165.61 X
	Revenue	3.55 M
	Gross Profit	240.74 M
	EBITDA	(561.51 M)
	Net Income	(609.69 M)
	Cash And Equivalents	416.5 M
	Cash Per Share	3.93 X
	Total Debt	117.37 M
	Debt To Equity	0.17 %
	Current Ratio	3.37 X
	Book Value Per Share	2.66 X
	Cash Flow From Operations	(462.85 M)
	Short Ratio	8.94 X
	Earnings Per Share	(5.00) X
	Price To Earnings To Growth	(1.32) X
	Target Price	45.38
	Number Of Employees	525
	Beta	0.93
	Market Capitalization	3.25 B
	Total Asset	1.14 B
	Retained Earnings	(1.63 B)
	Working Capital	592.3 M
	Current Asset	90.5 M
	Current Liabilities	25.64 M
	Net Asset	1.14 B

About Arrowhead Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Arrowhead Stock

0.37	BHC	Bausch Health Companies	Pair Corr
0.35	HCM	HUTCHMED DRC	Pair Corr
0.32	GANX	Gain Therapeutics	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC